| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
45,560,000 |
| Market
Cap: |
12.06(M) |
| Last
Volume: |
1,167,076 |
Avg
Vol: |
536,427 |
| 52
Week Range: |
$0.2646 - $0.2646 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Protalix BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system. Co.'s proprietary ProCellEx platform is being used to manufacture its marketed product, Elelyso®, for the treatment of Gaucher disease. Co. is also developing, via ProCellEx, a pipeline of products. Co.'s clinical development program for pegunigalsidase alfa, or PRX-102, for the potential treatment of Fabry disease. In addition, Co. is developing uricase, or PRX-115, for the treatment of refractory gout.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
64,516 |
174,516 |
| Total Buy Value |
$0 |
$0 |
$90,484 |
$246,299 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
1 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shaaltiel Yoseph |
Executive VP, R&D |
• • – |
2009-05-14 |
4 |
S |
$3.85 |
$38,500 |
D/D |
(10,000) |
1,463,754 |
|
- |
|
| Shaaltiel Yoseph |
Executive VP, R&D |
• • – |
2009-05-13 |
4 |
S |
$3.51 |
$70,200 |
D/D |
(20,000) |
1,473,754 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-05-12 |
4 |
D |
$3.48 |
$12,427 |
I/I |
(3,571) |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-05-12 |
4 |
OE |
$0.12 |
$12,429 |
I/I |
103,571 |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-05-12 |
4 |
AS |
$3.41 |
$190,619 |
I/I |
(55,900) |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-05-11 |
4 |
AS |
$3.41 |
$132,649 |
I/I |
(38,900) |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-05-08 |
4 |
AS |
$3.40 |
$17,680 |
I/I |
(5,200) |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-05-06 |
4 |
D |
$3.06 |
$9,367 |
I/I |
(3,061) |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-05-06 |
4 |
OE |
$0.12 |
$9,367 |
I/I |
78,061 |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-05-06 |
4 |
AS |
$3.01 |
$60,200 |
I/I |
(20,000) |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-05-05 |
4 |
AS |
$3.07 |
$66,312 |
I/I |
(21,600) |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-05-04 |
4 |
AS |
$3.01 |
$100,534 |
I/I |
(33,400) |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-04-20 |
4 |
D |
$2.55 |
$6,296 |
I/I |
(2,469) |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-04-20 |
4 |
OE |
$0.12 |
$6,296 |
I/I |
52,469 |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-04-20 |
4 |
AS |
$2.51 |
$83,583 |
I/I |
(33,300) |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-04-17 |
4 |
AS |
$2.56 |
$25,600 |
I/I |
(10,000) |
0 |
|
- |
|
| Aviezer David |
President & CEO |
• • – |
2009-04-16 |
4 |
AS |
$2.50 |
$16,750 |
I/I |
(6,700) |
0 |
|
- |
|
| Shaaltiel Yoseph |
Executive VP, R&D |
• • – |
2009-03-13 |
4 |
S |
$2.18 |
$18,094 |
D/D |
(8,300) |
1,493,754 |
|
- |
|
| Yossi Maimon |
VP, Chief Financial Officer |
• – – |
2009-03-13 |
4 |
S |
$2.23 |
$16,725 |
I/I |
(7,500) |
0 |
|
- |
|
| Yossi Maimon |
VP, Chief Financial Officer |
• – – |
2009-03-13 |
4 |
D |
$2.16 |
$38,686 |
I/I |
(17,910) |
0 |
|
- |
|
| Yossi Maimon |
VP, Chief Financial Officer |
• – – |
2009-03-13 |
4 |
OE |
$0.97 |
$38,686 |
I/I |
39,800 |
0 |
|
- |
|
| Yossi Maimon |
VP, Chief Financial Officer |
• – – |
2009-03-12 |
4 |
S |
$2.22 |
$71,575 |
I/I |
(32,241) |
0 |
|
- |
|
| Yossi Maimon |
VP, Chief Financial Officer |
• – – |
2009-03-11 |
4 |
S |
$2.30 |
$20,353 |
I/I |
(8,849) |
0 |
|
- |
|
| Frost Gamma Investment Trust |
10% Owner |
– – • |
2008-10-10 |
4 |
B |
$1.62 |
$8,196 |
I/I |
5,000 |
9,781,273 |
1.5 |
- |
|
| Bar-Shalev Amos |
Director |
– • – |
2008-07-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,186,046 |
|
- |
|
182 Records found
|
|
Page 6 of 8 |
|
|
